Americans as young as 18 with a chronic condition can now receive an RSV vaccine after Pfizer snagged expanded FDA approval ...

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

智通财经获悉，美国食品药品监督管理局(FDA)已批准辉瑞公司(PFE.US)的呼吸道合胞病毒(RSV)疫苗Abrysvo用于18至59岁下呼吸道疾病风险增加的人群。这些疾病包括肥胖、糖尿病、慢性阻塞性肺病、心力衰竭、慢性肾病和哮喘。扩大批准是基于3期 ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

The FDA approved Pfizer's Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...